Compare FIEE & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | AKTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.4M |
| IPO Year | N/A | N/A |
| Metric | FIEE | AKTX |
|---|---|---|
| Price | $2.46 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | N/A | ★ 1.3M |
| Earning Date | N/A | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.26 |
| 52 Week High | N/A | $1.73 |
| Indicator | FIEE | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 37.73 |
| Support Level | $1.65 | $0.26 |
| Resistance Level | $2.59 | $0.36 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 84.51 | 38.13 |
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.